PKR-Mediated Phosphorylation of eIF2a and CHK1 Is Associated with Doxorubicin-Mediated Apoptosis in HCC1143 Triple-Negative Breast Cancer Cells
<p>Doxorubicin induces DNA damage and apoptosis in HCC1143 triple-negative breast cancer cells. (<b>A</b>,<b>B</b>) Cells were treated with doxorubicin for the indicated time period or dose. DNA was extracted from cells and electrophoresed on agarose gels. Cisplatin (cis) was used as a positive control. (<b>C</b>,<b>D</b>) Cells were treated with the indicated concentrations of doxorubicin for 48 h and stained with Hoechst 33342, at room temperature, for 10 min. Nuclear morphological changes were observed using a confocal laser scanning microscope (magnification 100×). Fragmented nuclei are indicated by arrows, and the lower left squares are enlarged representative images (<b>C</b>). Scale bar is 100 μm. Fragmented nuclei were counted using a confocal laser scanning microscope (<b>D</b>). (<b>E</b>). HCC1143 cells were treated with doxorubicin at various concentrations for 48 h and MTT assay was performed to measure viability of cells. (<b>F</b>,<b>G</b>) Cells were treated with 1.5 μM doxorubicin for the indicated time period (<b>F</b>) or with increasing concentrations of doxorubicin for 48 h. (<b>G</b>) Immunoblotting analyses were conducted using specific antibodies against PARP, cleaved form of caspase-7 (c-Cas-7), and β-actin. Arrowhead indicates cleaved form of PARP-1.</p> "> Figure 2
<p>Doxorubicin-mediated activation of protein kinase R (PKR), but not PKR-like ER kinase (PERK), is responsible for eukaryotic initiation factor 2 alpha (eIF2α) phosphorylation in HCC1143 cells. (<b>A</b>,<b>B</b>) Cells were treated with 2 μM doxorubicin for the indicated time period and analyzed via immunoblotting using antibodies against phosphorylated form of eIF2α (p-eIF2α), eIF2α, phosphorylated form of PKR (p-PKR), PKR, PERK, and β-Actin. Tg was used as a positive control. Fold change is the ratios of p-PKR to PKR and p-eIF2α to eIF2α. (<b>C</b>) Cells were treated with the indicated concentrations of doxorubicin for 32 h and analyzed via immunoblotting using specific antibodies against p-PKR, PKR, p-eIF2α, eIF2α, and β-Actin. (<b>D</b>) Cells pretreated with or without 0.5 μM C16 for 1 h were treated with the indicated concentrations of doxorubicin for 32 h and analyzed via immunoblotting using specific antibodies against p-PKR, PKR, p-eIF2α, eIF2α, and β-Actin. Fold change is the ratios of p-PKR to PKR and p-eIF2α to eIF2α.</p> "> Figure 3
<p>Inhibition of PKR reduces the doxorubicin-mediated apoptosis of HCC1143 cells. (<b>A</b>) Cells pretreated with or without 0.5 μM C16 for 1 h were treated with the indicated concentrations of doxorubicin for 48 h. DNA extracted from the cells was electrophoresed on agarose gels. (<b>B</b>,<b>C</b>) Cells pretreated with or without 0.5 μM C16 for 1 h were treated with 0.5 μM doxorubicin for 48 h and stained with Hoechst 33342, at room temperature, for 10 min. Nuclear morphological changes were observed using a confocal laser scanning microscope (magnification 100×). Scale bar is 100 μm. Lower-left squares are enlarged representative images (<b>B</b>). In each group, fragmented nuclei were counted using a confocal laser scanning microscope. Statistical significance was analyzed via the Student’s <span class="html-italic">t</span>-test (*** <span class="html-italic">p</span> < 0.001) (<b>C</b>). (<b>D</b>) Cells pretreated with or without 0.5 μM C16 for 1 h were treated with the indicated concentrations of doxorubicin for 32 h and analyzed via immunoblotting using specific antibodies against PARP, c-Cas-7, and β-actin. Arrowhead indicates cleaved form of PARP-1.</p> "> Figure 4
<p>Doxorubicin-induced PKR-mediated apoptosis is caused by eIF2α/CHOP signaling and checkpoint kinase 1 (CHK1) phosphorylation in HCC1143 cells. (<b>A</b>,<b>B</b>) Cells pretreated with or without 0.5 μM C16 for 1 h were treated with 2 μM doxorubicin for the indicated time period. RT-PCR was performed using specific primers for C/EBP homologous protein (CHOP) and β-actin (<b>A</b>). Cells were treated with 10 μg/mL puromycin for 10 min. Cell lysates were subjected to immunoblotting analysis using specific antibodies against puromycin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (<b>B</b>). (<b>C</b>) Cells were treated with 2 μM doxorubicin for the indicated time period and analyzed via immunoblotting using specific antibodies against CHK1, phosphorylated form of CHK1 (p-CHK1), and β-Actin. (<b>D</b>,<b>E</b>) Cells pretreated with or without 0.5 μM C16 for 1 h were treated with the indicated concentrations of doxorubicin for 32 h (<b>D</b>) or 2 μM doxorubicin for the indicated time period (<b>E</b>) and analyzed via immunoblotting using specific antibodies against p-CHK1, CHK1, p-p53, p53, and β-Actin. Fold change is the ratio of p-CHK1 to CHK1 (<b>D</b>) and the ratios of p-CHK1 to CHK1 and p-p53 to p53 (<b>E</b>).</p> ">
Abstract
:1. Introduction
2. Results
2.1. Doxorubicin Induces DNA Damage and Apoptosis in HCC1143 TNBC Cells
2.2. Doxorubicin-Mediated Activation of PKR, but Not PERK, Is Responsible for eIF2α Phosphorylation in HCC1143 Cells
2.3. Inhibition of PKR Reduces the Doxorubicin-Mediated Apoptosis of HCC1143 Cells
2.4. Doxorubicin-Induced PKR-Mediated Apoptosis Is Caused by eIF2α/CHOP Signaling and CHK1 Phosphorylation in HCC1143 Cells
3. Discussion
4. Materials and Methods
4.1. Reagents
4.2. Cell Culture
4.3. Measurement of Apoptosis Using Microscopy
4.4. Measurement of DNA Fragmentation
4.5. Immunoblotting Analysis
4.6. RT-PCR and PCR Primers
4.7. Cell Cycle Analysis
4.8. Statistical Analysis
5. Conclusions
- Doxorubicin-mediated activation of PKR, but not PERK, is responsible for eIF2α phosphorylation in HCC1143 triple-negative breast cancer (TNBC) cells.
- Inhibition of PKR reduces the doxorubicin-mediated apoptosis of HCC1143 TNBC cells.
- Doxorubicin-induced PKR-mediated apoptosis is caused by eIF2α/CHOP signaling in HCC1143 TNBC cells.
- Doxorubicin-induced PKR-mediated apoptosis is caused by CHK1 phosphorylation in HCC1143 TNBC cells.
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Watanabe, T.; Imamura, T.; Hiasa, Y. Roles of protein kinase R in cancer: Potential as a therapeutic target. Cancer Sci. 2018, 109, 919–925. [Google Scholar] [CrossRef] [Green Version]
- Garcia, M.A.; Gil, J.; Ventoso, I.; Guerra, S.; Domingo, E.; Rivas, C.; Esteban, M. Impact of protein kinase PKR in cell biology: From antiviral to antiproliferative action. Microbiol. Mol. Biol. Rev. MMBR 2006, 70, 1032–1060. [Google Scholar] [CrossRef] [Green Version]
- Bennett, R.L.; Carruthers, A.L.; Hui, T.; Kerney, K.R.; Liu, X.; May, W.S., Jr. Increased expression of the dsRNA-activated protein kinase PKR in breast cancer promotes sensitivity to doxorubicin. PLoS ONE 2012, 7, e46040. [Google Scholar] [CrossRef] [Green Version]
- Cheng, X.; Byrne, M.; Brown, K.D.; Konopleva, M.Y.; Kornblau, S.M.; Bennett, R.L.; May, W.S. PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice. Blood 2015, 126, 1585–1594. [Google Scholar] [CrossRef] [Green Version]
- Martinez, N.W.; Gomez, F.E.; Matus, S. The Potential Role of Protein Kinase R as a Regulator of Age-Related Neurodegeneration. Front. Aging Neurosci. 2021, 13, 638208. [Google Scholar] [CrossRef]
- Blalock, W.L.; Bavelloni, A.; Piazzi, M.; Faenza, I.; Cocco, L. A role for PKR in hematologic malignancies. J. Cell. Physiol. 2010, 223, 572–591. [Google Scholar] [CrossRef]
- Scheuner, D.; Patel, R.; Wang, F.; Lee, K.; Kumar, K.; Wu, J.; Nilsson, A.; Karin, M.; Kaufman, R.J. Double-stranded RNA-dependent protein kinase phosphorylation of the alpha-subunit of eukaryotic translation initiation factor 2 mediates apoptosis. J. Biol. Chem. 2006, 281, 21458–21468. [Google Scholar] [CrossRef] [Green Version]
- Donnelly, N.; Gorman, A.M.; Gupta, S.; Samali, A. The eIF2alpha kinases: Their structures and functions. Cell. Mol. Life Sci. CMLS 2013, 70, 3493–3511. [Google Scholar] [CrossRef]
- Wek, R.C. Role of eIF2alpha Kinases in Translational Control and Adaptation to Cellular Stress. Cold Spring Harb. Perspect. Biol. 2018, 10, a032870. [Google Scholar] [CrossRef]
- Hetz, C.; Zhang, K.; Kaufman, R.J. Mechanisms, regulation and functions of the unfolded protein response. Nat. Rev. Mol. Cell Biol. 2020, 21, 421–438. [Google Scholar] [CrossRef]
- Oyadomari, S.; Mori, M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 2004, 11, 381–389. [Google Scholar] [CrossRef] [Green Version]
- Cuddihy, A.R.; Li, S.; Tam, N.W.; Wong, A.H.; Taya, Y.; Abraham, N.; Bell, J.C.; Koromilas, A.E. Double-stranded-RNA-activated protein kinase PKR enhances transcriptional activation by tumor suppressor p53. Mol. Cell. Biol. 1999, 19, 2475–2484. [Google Scholar] [CrossRef] [Green Version]
- Fremont, M.; Vaeyens, F.; Herst, C.V.; De Meirleir, K.L.; Englebienne, P. Double-stranded RNA-dependent protein kinase (PKR) is a stress-responsive kinase that induces NFkappaB-mediated resistance against mercury cytotoxicity. Life Sci. 2006, 78, 1845–1856. [Google Scholar] [CrossRef]
- Meurs, E.F.; Galabru, J.; Barber, G.N.; Katze, M.G.; Hovanessian, A.G. Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. USA 1993, 90, 232–236. [Google Scholar] [CrossRef] [Green Version]
- Blalock, W.L.; Bavelloni, A.; Piazzi, M.; Tagliavini, F.; Faenza, I.; Martelli, A.M.; Follo, M.Y.; Cocco, L. Multiple forms of PKR present in the nuclei of acute leukemia cells represent an active kinase that is responsive to stress. Leukemia 2011, 25, 236–245. [Google Scholar] [CrossRef] [Green Version]
- McGowan, J.V.; Chung, R.; Maulik, A.; Piotrowska, I.; Walker, J.M.; Yellon, D.M. Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc. Drugs Ther. 2017, 31, 63–75. [Google Scholar] [CrossRef] [Green Version]
- Thorn, C.F.; Oshiro, C.; Marsh, S.; Hernandez-Boussard, T.; McLeod, H.; Klein, T.E.; Altman, R.B. Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharm. Genom. 2011, 21, 440–446. [Google Scholar] [CrossRef]
- Gewirtz, D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57, 727–741. [Google Scholar] [CrossRef]
- Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56, 185–229. [Google Scholar] [CrossRef] [Green Version]
- Kunkeaw, N.; Lee, Y.S.; Im, W.R.; Jang, J.J.; Song, M.J.; Yang, B.; Park, J.L.; Kim, S.Y.; Ku, Y.; Kim, Y.; et al. Mechanism mediated by a noncoding RNA, nc886, in the cytotoxicity of a DNA-reactive compound. Proc. Natl. Acad. Sci. USA 2019, 116, 8289–8294. [Google Scholar] [CrossRef]
- Diana, A.; Carlino, F.; Franzese, E.; Oikonomidou, O.; Criscitiello, C.; De Vita, F.; Ciardiello, F.; Orditura, M. Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. Cancers 2020, 12, 819. [Google Scholar] [CrossRef] [Green Version]
- Nofech-Mozes, S.; Trudeau, M.; Kahn, H.K.; Dent, R.; Rawlinson, E.; Sun, P.; Narod, S.A.; Hanna, W.M. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res. Treat. 2009, 118, 131–137. [Google Scholar] [CrossRef] [PubMed]
- De Ruijter, T.C.; Veeck, J.; de Hoon, J.P.; van Engeland, M.; Tjan-Heijnen, V.C. Characteristics of triple-negative breast cancer. J. Cancer Res. Clin. Oncol. 2011, 137, 183–192. [Google Scholar] [CrossRef] [Green Version]
- Tan, A.R.; Swain, S.M. Therapeutic strategies for triple-negative breast cancer. Cancer J. 2008, 14, 343–351. [Google Scholar] [CrossRef]
- Carey, L.A.; Dees, E.C.; Sawyer, L.; Gatti, L.; Moore, D.T.; Collichio, F.; Ollila, D.W.; Sartor, C.I.; Graham, M.L.; Perou, C.M. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2007, 13, 2329–2334. [Google Scholar] [CrossRef] [Green Version]
- Peidis, P.; Papadakis, A.I.; Muaddi, H.; Richard, S.; Koromilas, A.E. Doxorubicin bypasses the cytoprotective effects of eIF2alpha phosphorylation and promotes PKR-mediated cell death. Cell Death Differ. 2011, 18, 145–154. [Google Scholar] [CrossRef] [Green Version]
- Gil, J.; Esteban, M. Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): Mechanism of action. Apoptosis Int. J. Program. Cell Death 2000, 5, 107–114. [Google Scholar] [CrossRef]
- Li, Y.; Guo, Y.; Tang, J.; Jiang, J.; Chen, Z. New insights into the roles of CHOP-induced apoptosis in ER stress. Acta Biochim. Et Biophys. Sin. 2014, 46, 629–640. [Google Scholar] [CrossRef] [Green Version]
- Koromilas, A.E. Roles of the translation initiation factor eIF2alpha serine 51 phosphorylation in cancer formation and treatment. Biochim. Biophys. Acta 2015, 1849, 871–880. [Google Scholar] [CrossRef]
- Krishnamoorthy, T.; Pavitt, G.D.; Zhang, F.; Dever, T.E.; Hinnebusch, A.G. Tight binding of the phosphorylated alpha subunit of initiation factor 2 (eIF2alpha) to the regulatory subunits of guanine nucleotide exchange factor eIF2B is required for inhibition of translation initiation. Mol. Cell. Biol. 2001, 21, 5018–5030. [Google Scholar] [CrossRef]
- Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88, 323–331. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Song, Y.; Wan, X.; Gao, L.; Pan, Y.; Xie, W.; Wang, H.; Guo, J. Activated PKR inhibits pancreatic beta-cell proliferation through sumoylation-dependent stabilization of P53. Mol. Immunol. 2015, 68, 341–349. [Google Scholar] [CrossRef] [PubMed]
- Abramson, V.G.; Lehmann, B.D.; Ballinger, T.J.; Pietenpol, J.A. Subtyping of triple-negative breast cancer: Implications for therapy. Cancer 2015, 121, 8–16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bansal, N.; Adams, M.J.; Ganatra, S.; Colan, S.D.; Aggarwal, S.; Steiner, R.; Amdani, S.; Lipshultz, E.R.; Lipshultz, S.E. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardio-Oncology 2019, 5, 18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bu, Y.; Diehl, J.A. PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development. J. Cell. Physiol. 2016, 231, 2088–2096. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, Z.; Lv, Y.; Zhao, N.; Guan, G.; Wang, J. Protein kinase R-like ER kinase and its role in endoplasmic reticulum stress-decided cell fate. Cell Death Dis. 2015, 6, e1822. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guo, L.; Chi, Y.; Xue, J.; Ma, L.; Shao, Z.; Wu, J. Phosphorylated eIF2alpha predicts disease-free survival in triple-negative breast cancer patients. Sci. Rep. 2017, 7, 44674. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Iurlaro, R.; Munoz-Pinedo, C. Cell death induced by endoplasmic reticulum stress. FEBS J. 2016, 283, 2640–2652. [Google Scholar] [CrossRef] [Green Version]
- McCullough, K.D.; Martindale, J.L.; Klotz, L.O.; Aw, T.Y.; Holbrook, N.J. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol. Cell. Biol. 2001, 21, 1249–1259. [Google Scholar] [CrossRef] [Green Version]
- Yang, F.; Teves, S.S.; Kemp, C.J.; Henikoff, S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochim. Biophys. Acta 2014, 1845, 84–89. [Google Scholar] [CrossRef]
- Roos, W.P.; Thomas, A.D.; Kaina, B. DNA damage and the balance between survival and death in cancer biology. Nat. Rev. Cancer 2016, 16, 20–33. [Google Scholar] [CrossRef] [PubMed]
- Zhao, H.; Piwnica-Worms, H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell. Biol. 2001, 21, 4129–4139. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ho, C.C.; Siu, W.Y.; Chow, J.P.; Lau, A.; Arooz, T.; Tong, H.Y.; Ng, I.O.; Poon, R.Y. The relative contribution of CHK1 and CHK2 to Adriamycin-induced checkpoint. Exp. Cell Res. 2005, 304, 1–15. [Google Scholar] [CrossRef] [PubMed]
- Shieh, S.Y.; Ahn, J.; Tamai, K.; Taya, Y.; Prives, C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 2000, 14, 289–300. [Google Scholar] [CrossRef] [PubMed]
- Lin, R.W.; Ho, C.J.; Chen, H.W.; Pao, Y.H.; Chen, L.E.; Yang, M.C.; Huang, S.B.; Wang, S.; Chen, C.H.; Wang, C. P53 enhances apoptosis induced by doxorubicin only under conditions of severe DNA damage. Cell Cycle 2018, 17, 2175–2186. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yoon, C.H.; Lee, E.S.; Lim, D.S.; Bae, Y.S. PKR, a p53 target gene, plays a crucial role in the tumor-suppressor function of p53. Proc. Natl. Acad. Sci. USA 2009, 106, 7852–7857. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vera, J.; Raatz, Y.; Wolkenhauer, O.; Kottek, T.; Bhattacharya, A.; Simon, J.C.; Kunz, M. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells. Cell. Signal. 2015, 27, 951–960. [Google Scholar] [CrossRef]
- Kung, C.P.; Cottrell, K.A.; Ryu, S.; Bramel, E.R.; Kladney, R.D.; Bao, E.A.; Freeman, E.C.; Sabloak, T.; Maggi, L., Jr.; Weber, J.D. Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer. Oncogene 2021, 40, 189–202. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lee, S.; Jee, H.-Y.; Lee, Y.-G.; Shin, J.-I.; Jeon, Y.-J.; Kim, J.-B.; Seo, H.-e.; Lee, J.-Y.; Lee, K. PKR-Mediated Phosphorylation of eIF2a and CHK1 Is Associated with Doxorubicin-Mediated Apoptosis in HCC1143 Triple-Negative Breast Cancer Cells. Int. J. Mol. Sci. 2022, 23, 15872. https://doi.org/10.3390/ijms232415872
Lee S, Jee H-Y, Lee Y-G, Shin J-I, Jeon Y-J, Kim J-B, Seo H-e, Lee J-Y, Lee K. PKR-Mediated Phosphorylation of eIF2a and CHK1 Is Associated with Doxorubicin-Mediated Apoptosis in HCC1143 Triple-Negative Breast Cancer Cells. International Journal of Molecular Sciences. 2022; 23(24):15872. https://doi.org/10.3390/ijms232415872
Chicago/Turabian StyleLee, Sol, Ha-Yeon Jee, Yoon-Gyeong Lee, Jong-Il Shin, Yong-Joon Jeon, Ji-Beom Kim, Hye-eun Seo, Ji-Yeon Lee, and Kyungho Lee. 2022. "PKR-Mediated Phosphorylation of eIF2a and CHK1 Is Associated with Doxorubicin-Mediated Apoptosis in HCC1143 Triple-Negative Breast Cancer Cells" International Journal of Molecular Sciences 23, no. 24: 15872. https://doi.org/10.3390/ijms232415872
APA StyleLee, S., Jee, H.-Y., Lee, Y.-G., Shin, J.-I., Jeon, Y.-J., Kim, J.-B., Seo, H.-e., Lee, J.-Y., & Lee, K. (2022). PKR-Mediated Phosphorylation of eIF2a and CHK1 Is Associated with Doxorubicin-Mediated Apoptosis in HCC1143 Triple-Negative Breast Cancer Cells. International Journal of Molecular Sciences, 23(24), 15872. https://doi.org/10.3390/ijms232415872